ClinicalTrials.gg
CompletedNCT03499444Updated Jun 9, 2023

A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor

A Phase 1 interventional study of Rucaparib in Advanced Solid Tumor, sponsored by pharmaand GmbH. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by pharmaand GmbH · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

This is a Phase 1 open-label, dose-escalation, safety and pharmacokinetic study of rucaparib administered twice daily (BID) to Japanese patients with a solid tumor who have failed previous standard treatment for their cancer. A recommended dose of rucaparib for Japanese patients will be determined in a dose-escalation portion and then further evaluated in a dose-expansion portion of the study.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

pharmaand GmbH is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 20 years of age at the time the form is signed and of Japanese ethnicity (ie, both parents are native Japanese and were born in Japan).
  • Have a solid tumor that has progressed on standard treatment:

    • For patients enrolled in the dose-escalation portion, has confirmed solid tumor that is locally recurrent or
    • For patients enrolled in the dose-expansion portion, has high-grade serous ovarian cancer, or BRCA 1/2 mutated breast cancer, or other solid tumor with BRCA 1/2 or related gene mutation
  • Have to have evaluable disease (i.e. disease can be followed on scans.)
  • Be willing and able to fast for at least 14 hours

Exclusion criteria

Exclusion Criteria:

  • Active second
  • Prior treatment with any PARP inhibitor
  • Symptomatic and/or untreated
  • Women who are breastfeeding or pregnant
  • Pre-existing duodenal stent and/or any gastrointestinal disorder that would interfere with drug absorption
  • Requires regular blood transfusions
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Oral Rucaparib monotherapy

    Part I: Dose Escalation, Part II: Dose Expansion (Additional patients will be enrolled at the recommended dose as defined in Part I of the study.)

    Drug: Rucaparib

Interventions

  • Rucaparib will be administered twice daily

    Also known as: CO-338

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related Adverse Events (AEs) as assessed by CTCAE v4.03 as a measure of safety and tolerability

    Time frame: From enrollment to completion of Part I (up to 12 months)

  2. Number of participants with serious AEs as a measure of safety and tolerability

    Time frame: From enrollment to completion of Part I (up to 12 months)

  3. Number of participants with worsening laboratory values as a measure of safety and tolerability

    Time frame: From enrollment to completion of Part I (up to 12 months)

Secondary outcomes

  1. Dose-limiting toxicities (DLTs) during Cycle 1 of treatment

    Time frame: From enrollment to completion of Part I (up to 12 months)

  2. Area under the plasma concentration versus time curve [AUC]

    Time frame: From enrollment to completion of Part I (up to 12 months)

  3. Peak Plasma Concentration [Cmax]

    Time frame: From enrollment to completion of Part I (up to 12 months)

  4. Total Plasma Clearance [CI/F]

    Time frame: From enrollment to completion of Part I (up to 12 months)

  5. Response to treatment according to RECIST Version 1.1

    Time frame: From enrollment to primary completion of study (up to 3 years)

07

Study locations

3 sites
  • Division of Medical Oncology, Hyogo Cancer Center
    Akashi, Hyogo 673-8558, Japan
  • Department of Gynecologic Oncology, Saitama Medical Univeristy international Medical Center
    Hidaka, Saitama 350-1298, Japan
  • Department of Breast and Medical Oncology, National Cancer Center Hospital
    Tsukiji, Tokyo 104-0045, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jun 2019, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2018
First posted
Apr 17, 2018
StartActual
Feb 6, 2018
Primary completionActual
Jun 18, 2019
CompletionActual
Apr 13, 2022
Last update
Jun 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03499444
Lead sponsor
pharmaand GmbH
Responsible party
Sponsor
First posted
Apr 17, 2018
Start date
Feb 6, 2018
Primary completion
Jun 18, 2019
Completion
Apr 13, 2022
Last update
Jun 9, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rucaparib

Start the discussion